Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
- NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020
- Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers
- Regulatory filing for rimegepant in Europe submitted and accepted for review by European Medicines Agency for dual-acting (acute and prevention) indication for treatment of migraine
- Life-cycle management studies for CGRP-antagonist program underway, including initiation of Phase 4 study of NURTEC ODT in pediatric migraine
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Biohaven s BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
primepublishers.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from primepublishers.com Daily Mail and Mail on Sunday newspapers.